Review:
Global Threats and the Control of Multidrug-Resistant Tuberculosis
Kazuo Kobayashi*, Manabu Ato*,
and Sohkichi Matsumoto**
*Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
**Department of Bacteriology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
- [1] D. B. Young, M. D. Perkins, and C. E. Barry III, “Confronting the Scientific Obstacles to Global Control of Tuberculosis,” J. Clin. Invest. 118, pp. 1255-1265, 2008.
- [2] Stop TB Partnership, The Global Plan to Stop TB,
http://www.stoptb.org/global/plan/
[accessed at January 6, 2011] - [3] D. M. Morens, G. K. Folkers, and A. S. Fauci, “The Challenge of Emerging and Re-Emerging Infectious Diseases,” Nature 430, pp. 242-249, 2004.
- [4] E. Nathanson, P. Nunn, M. Uplekar, K. Floyd, E. Jaramillo, K. Lonnroth, D. Weil, and M. Raviglione, “MDR Tuberculosis. Critical Steps for Prevention and Control,” N. Engl. J. Med. 363, pp. 1050-1058, 2010.
- [5] World Health Organization. Stop TB Partnership. 2010/2011 Tuberculosis. Global Facts,
http://www.who.int/tb/publications/2010/factsheet_tb_2010.pdf - [6] Ministry of Health, Labour and Welfare of Japan,
http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou03/09.html
[accessed at January 6, 2011]. - [7] Ministry of Health, Labour and Welfare of Japan, The Law Regarding Infectious Disease Prevention and Medical Care for the Patients,
http://www.mhlw.go.jp/english/wp/wp-hw2/part2/p3_0028.pdf
[accessed at February 10, 2011] - [8] Stop TB Partnership Japan, Drug-resistant Tuberculosis, http://www.stoptb.jp/about/mdr_tb/
[accessed at February 10, 2011] - [9] World Health Organization, Multidrug and Extensively Drugresistant TB (M/XDR-TB), 2010 Global Report on Surveillance and Response,
http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf - [10] Nunn, P. Stop TB Partnership, MDR, XDR TB and HIV: Global Data, Approaches, and Operational Research Issues, http://www.stoptb.org/wg/tb_hiv/assets/documents/MDR_XD˜1.pdf
- [11] P. M. Small andM. Pai, “Tuberculosis Diagnosis,” Time for a Game Change, N. Engl. J. Med. 363, pp. 1070-1071, 2010.
- [12] D. B. Young, M. D. Perkins, and C. E. Barry III, “Confronting the Scientific Obstacles to Global Control of Tuberculosis,” J. Clin. Invest. 118, pp. 1255-1265, 2008.
- [13] I. Comas and S. Gagneux, “The Past and Future of Tuberculosis Research,” PLoS Pathog. 5: e1000600, 2009.
- [14] The New Diagnostics Working Group of the Stop TB Partnership, Pathways to better Diagnostics for Tuberculosis, A Blueprint for the Development of TB Diagnostics,
http://www.stoptb.org/wg/new_diagnostics/assets/documents/BluePrintTB_annex_web.pdf - [15] D. A. J. Moore, C. A.W. Evans, R. H. Gilman, L. Caviedes, J. Coronel, A. Vivar, E. Sanchez, Y. Pinedo, J. C. Saravia, C. Salazar, R. Oberhelman,M. G. Hollm-Delgado, D. LaChira, A. R. Escombe, and J. S. Friedland, “Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB,” N. Engl. J. Med. 355, pp. 1539-1550, 2006.
- [16] M. Viveiros, C. Leandro, L. Rodrigues, J. Almeida, R. Bettencourt, I. Couto, L. Carrilho, J. Diogo, A. Fonseca, L. Lito, J. Lopes, T. Pacheco, M. Pessanha, J. Quirim, L. Sancho, M. Salfinger, and L. Amaral, “Direct Application of the INNO-LiPA Rif.TB Line-Probe Assay for Rapid Identification of Mycobacterium tuberculosis Complex Strains and Detection of Rifampin Resistance in 360 Smear-Positive Respiratory Specimens from an Area of High Incidence of Multidrug-Resistant Tuberculosis,” J. Clin. Microbiol. 43, pp. 4880-4884, 2005.
- [17] C. C. Boehme, P. Nabeta, D. Hillemann, M. P. Nicol, S. Shenai, F. Krapp, J. Allen, R. Tahirli, R. Blakemore, R. Rustomjee, A. Milovic, M. Jones, S. M. O’Brien, D. H. Persing, S. Ruesch-Gerdes, E. Gotuzzo, C. Rodrigues, D. Alland, and M. D. Perkins, “Rapid Molecular Detection of Tuberculosis and Rifampin Resistance,” N. Engl. J. Med. 363, pp. 1005-1015, 2010.
- [18] D. G. Russell, C. E. Barry III, and J. L. Flynn, “Tuberculosis: What We Don’t Know Can, and Does, Hurt Us,” Science 328, pp. 852-856, 2010.
- [19] D. J. Murphy and J. R. Brown, “Novel Drug Target Strategies Against Mycobacterium tuberculosis,” Curr. Opin. Microbiol. 11, pp. 422-427, 2008.
- [20] A. Koul, E. Arnoult, N. Lounis, J. Guillemont, and A. Koen, “The Challenge of New Drug Discovery for Tuberculosis,” Nature 469, pp. 483-490, 2011.
- [21] B. V. Nikonenko, M. Protopopova, R. Samala, L. Erick, and C. A. Nacy, “Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs,” Antimicrob. Agents Chemother. 51, pp. 1563-1565, 2007.
- [22] A. H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J. C. Palomino, T. De Marez, R. P. G. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K. de Beule, K. Andries, and D. F. M. Neeley, “The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis,” N. Engl. J. Med. 360, pp. 2397-2405, 2009.
- [23] M. Matsumoto, H. Hashizume, T. Tomishige, M. i. Kawasaki, H. Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu, “A Nitro-Dihydro-Imidazooxazole Derivative with Promising Action Against Tuberculosis in Vitro and in Mice,” OPC-67683, PLoS Med. 3: e466, 2006.
- [24] R. Singh, U. Manjunatha, H. I. M. Boshoff, Y. H. Ha, P. Niyomrattanakit, R. Ledwidge, C. S. Dowd, Y. Lee, P. Kim, L. Zhang, S. Kang, T. H. Keller, J. Jiricek, and C. E. Barry III, “PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release,” Science 322, pp. 1392-1395, 2008.
- [25] K. Duncan and C. E. Barry III, “Prospects for New Antitubercular Drugs,” Curr. Opin. Microbiol. 7, pp. 460-465, 2004.
- [26] P. Andersen, “Tuberculosis Vaccines,” An Update. Nat. Rev. Microbiol. 5, pp. 484-487, 2007.
- [27] B. Beresford and J. C. Sadoff, “Update on Research and Development Pipeline: Tuberculosis Vaccines,” Clin. Infect. Dis. 50, pp. S178-S183, 2010.
- [28] C. R. Sander, A. A. Pathan, N. E. R. Beveridge, I. Poulton, A. Minassian, N. Alder, J. Van Wijgerden, A. V. S. Hill, F. V. Gleeson, R. J. O. Davies, G. Pasvol, and H. McShane, “Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis-Infected Individuals,” Am. J. Respir. Crit. Care Med. 179, pp. 724-733, 2009.
- [29] S. G. Reed, R. N. Coler, W. Dalemans, E. V. Tan, E. C. DeLa Cruz, R. J. Basaraba, I. M. Orme, Y. A. W. Skeiky, M. R. Alderson, K. D. Cowgill, J. P. Prieels, R. M. Abalos, M. C. Dubois, J. Cohen, P. Mettens, and Y. Lobet, “Defined Tuberculosis Vaccine, Mtb72F/AS02A, Evidence of Protection in Cynomolgus Monkeys,” Proc. Natl. Acad. Sci. USA 106, pp. 2301-2306, 2009.
This article is published under a Creative Commons Attribution-NoDerivatives 4.0 Internationa License.